Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

PLTRLONGDONG Aug. 21 at 7:41 AM

$ABCL big day coming

0 · Reply

Bullock3000 Aug. 21 at 2:50 AM

$ABCL What happened to all the Bulls ? Sell their shares and run? If so, it was a smart move.

0 · Reply

Rastafari Aug. 21 at 1:25 AM

$ABCL nice piece on Canadian TV: https://youtu.be/SNlhN6nujIM?is=NlUblaqpcZZ7Th1g

0 · Reply

Bullock3000 Aug. 20 at 8:20 PM

$ABCL sell it before it erodes your capital basis. These companies are created to make a "narrative" to produce volatility. Volatility is the product. The company has produced no registered product in 14 years because that is not the business they are in.

1 · Reply

Vogelito Aug. 20 at 8:12 PM

$ABCL mate you sound more and more desperate. You celebrate a day with -3,7% decline after a 185% spike upwards. If anyone’s a a bag holder it is you.

2 · Reply

Bullock3000 Aug. 20 at 7:53 PM

$ABCL Stocktwits has changed sentiment from bullish to bearish. That is how they see things.

0 · Reply

Stocktradesmoon Aug. 20 at 7:52 PM

$ABCL BEAUTIFUL CHART 📈. We will get to$15-$20 by NEXT WEEK! In Order to do that we need some Healthy Pullbacks. REMEMBER the LONGER the BASE the BIGGER the BREAKOUT!!! Nice buys and Consolidation happening here. $11.38 New SUPPORT for the NEXT LEG up to $15’ss and then we breathe a little and GO STRAIGHT to $20!!! DON’T be LEFT OUT!!

0 · Reply

Bullock3000 Aug. 20 at 7:50 PM

$ABCL There still. 13 minutes left to drop your bags. You can still buy back tomorrow, cheaper.

0 · Reply

Bullock3000 Aug. 20 at 7:47 PM

$ABCL Welcome to a new era of bag holding on a compant that has NO PRODUCTS, just dilution. EVERY TIME.

0 · Reply

Bullock3000 Aug. 20 at 7:40 PM

$ABCL Price is a bottomless pit below $10.92. That is only 62 cents away.

1 · Reply

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

2026-08-11T20:05:47.000Z - 9 days ago

AbCellera announces $200M common stock, warrants offering

Aug 11, 2026, 4:01 PM EDT - 9 days ago

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-08-11T13:35:37.000Z - 9 days ago

AbCellera price target raised to $30 from $12 at Truist

2026-08-10T19:55:32.000Z - 10 days ago

AbCellera price target raised to $25 from $13 at JonesResearch

Aug 10, 2026, 8:00 AM EDT - 10 days ago

AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 7:30 AM EDT - 10 days ago

AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 10 days ago

AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 10 days ago

AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:23 AM EDT - 10 days ago

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

Aug 10, 2026, 7:13 AM EDT - 10 days ago

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

2026-08-10T11:11:27.000Z - 10 days ago

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

Aug 10, 2026, 7:00 AM EDT - 10 days ago

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Aug 7, 2026, 4:30 PM EDT - 13 days ago

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

2026-08-06T12:20:50.000Z - 14 days ago

AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:12:02.000Z - 14 days ago

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

Aug 5, 2026, 5:00 PM EDT - 15 days ago

AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 15 days ago

AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 15 days ago

AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 15 days ago

AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 4:05 PM EDT - 15 days ago

AbCellera Reports Q2 2026 Business Results

2026-07-29T11:27:06.000Z - 22 days ago

AbCellera announces collaboration with Vertex Pharmaceuticals

VRTX

Jul 29, 2026, 7:00 AM EDT - 22 days ago

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

2026-07-09T21:29:02.000Z - 6 weeks ago

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

NUVB SERV UBER

Jul 7, 2026, 4:05 PM EDT - 6 weeks ago

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-07-07T10:35:14.000Z - 6 weeks ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ

2026-07-06T13:15:29.000Z - 6 weeks ago

AbCellera apponts Lynn Seely to board of directors

LYEL

Jul 6, 2026, 9:00 AM EDT - 6 weeks ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jun 17, 2026, 7:43 AM EDT - 2 months ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jun 17, 2026, 7:00 AM EDT - 2 months ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jun 5, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 4, 2026, 11:40 AM EDT - 2 months ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 3 months ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 4:05 PM EDT - 3 months ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 3 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 1, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 21, 2026, 1:30 PM EDT - 4 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 4 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 1, 2026, 4:05 PM EDT - 5 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 5 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 6 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 6 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 7 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 7 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 7:00 AM EST - 7 months ago

AbCellera Biologics Slides: Corporate presentation

Jan 12, 2026, 9:00 AM EST - 7 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 8 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 9 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 10 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 10 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 10 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 1 year ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 27, 2025, 9:00 AM EDT - 1 year ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 2 years ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

PLTRLONGDONG Aug. 21 at 7:41 AM

$ABCL big day coming

0 · Reply

Bullock3000 Aug. 21 at 2:50 AM

$ABCL What happened to all the Bulls ? Sell their shares and run? If so, it was a smart move.

0 · Reply

Rastafari Aug. 21 at 1:25 AM

$ABCL nice piece on Canadian TV: https://youtu.be/SNlhN6nujIM?is=NlUblaqpcZZ7Th1g

0 · Reply

Bullock3000 Aug. 20 at 8:20 PM

1 · Reply

Vogelito Aug. 20 at 8:12 PM

$ABCL mate you sound more and more desperate. You celebrate a day with -3,7% decline after a 185% spike upwards. If anyone’s a a bag holder it is you.

2 · Reply

Bullock3000 Aug. 20 at 7:53 PM

$ABCL Stocktwits has changed sentiment from bullish to bearish. That is how they see things.

0 · Reply

Stocktradesmoon Aug. 20 at 7:52 PM

0 · Reply

Bullock3000 Aug. 20 at 7:50 PM

$ABCL There still. 13 minutes left to drop your bags. You can still buy back tomorrow, cheaper.

0 · Reply

Bullock3000 Aug. 20 at 7:47 PM

$ABCL Welcome to a new era of bag holding on a compant that has NO PRODUCTS, just dilution. EVERY TIME.

0 · Reply

Bullock3000 Aug. 20 at 7:40 PM

$ABCL Price is a bottomless pit below $10.92. That is only 62 cents away.

1 · Reply

snowPOW Aug. 20 at 7:35 PM

$ABCL $MRNA interesting 🤔 Thanks for posting NN555

0 · Reply

snowPOW Aug. 20 at 7:34 PM

$ABCL ooh bears mad

0 · Reply

MoneyMacG Aug. 20 at 7:10 PM

$ABCL $RR $NTLA $MXL $VKTX good

0 · Reply

Bullock3000 Aug. 20 at 7:06 PM

$ABCL "Somebody" has sure been a placing a lot of net bearish positions in the options market, all the way to $3.

0 · Reply

Bullock3000 Aug. 20 at 6:58 PM

$ABCL without a coordinated Pump Day 1. If this holds to close, rest assured the insiders have gone net short on the stock they are holding. They can make ALOT of money shorting this from $12 to $7. Trading the volatility is worth much more than the actual company, which has ZERO PRODUCTS.

1 · Reply

wesfabian1 Aug. 20 at 6:49 PM

$ABCL decline is completely macro-centric question is will these blues about d-day heal by tomorrow or will it take until monday for a new 52 week high

0 · Reply

ITF Aug. 20 at 6:43 PM

$ABCL retesting 11.38 as it should before a possible spike to higher high's, looks great

0 · Reply

Bazziggr Aug. 20 at 6:01 PM

$ABCL profit taking continues

1 · Reply

snowPOW Aug. 20 at 5:52 PM

$BB what I'm watching in relation to this old news for the upcoming summit https://www.pm.gc.ca/en/news/news-releases/2026/04/17/prime-minister-carney-announces-first-ever-canada-investment-summit $TSAT and $ABCL too Obviously there's many more, but these are the ones on my radar.

0 · Reply

Bullock3000 Aug. 20 at 5:18 PM

$ABCL Cute chart, saw it onn X last night. What the chart doesn't address is immunogenicity. For BLA products, our bodies form new antibodies to destroy the BLA product. Each dose of the BLA adds immunogenicity. That's why the duration of efficacy for a BLA is months, not years, as in small molecules.

1 · Reply

daytwister1 Aug. 20 at 5:06 PM

$ABCL Ca n we close even ? :) i try fishing now 11,56

1 · Reply

Bullock3000 Aug. 20 at 4:55 PM

$ABCL Nobody is shorting common shares. It's still at 22% float, where it has been forever. So, this is an organic move which has been going on the past 2 weeks. The daily pump candles is all that has been keeping this up. If they stop ...

1 · Reply

Market Cap	3.68B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	6,180,700
Avg Vol	8,099,738
Day's Range	N/A - N/A
Shares Out	306.61M
Stochastic %K	85%
Beta	1.20
Analysts	Strong Sell
Price Target	$16.12